Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A
Titel:
Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A
Auteur:
Catenacci, D.V.T. Kang, Y.-K. Yoon, H.H. Shim, B.Y. Kim, S.T. Oh, D.-Y. Spira, A.I. Ulahannan, S.V. Avery, E.J. Boland, P.M. Chao, J. Chung, H.C. Gardner, F. Klempner, S.J. Lee, K.-W. Oh, S.C. Peguero, J. Sonbol, M.B. Shen, L. Moehler, M. Sun, J. Li, D. Rosales, M.K. Park, H.